Back to search
Pancreatic Ductal Adenocarcinoma (mPDAC)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Pancreatic Ductal Adenocarcinoma (mPDAC) trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Pancreatic Ductal Adenocarcinoma (mPDAC) trials you may qualify forThis is a Phase 2 trial evaluating the combination of cemiplimab with the standard of care chemotherapy agent gemcitabine for the treatment of patients with met…
By 2030, pancreatic adenocarcinoma could become the second leading cause of cancer-related death in France. To date, Pancreaticoduodenectomy (PD) is the standar…
This study adopts a randomized, open label, placebo-controlled, multicenter trial design. OS was the primary endpoint, and eligible subjects were randomly divid…
The purpose of this clinical trial is to assess the safety and tolerability of TTFields in combination with chemotherapy in adults with metastatic pancreatic ad…
The PANOVA-4 study is designed to evaluate the safety and efficacy of Tumor Treating Fields (TTFields) therapy together with atezolizumab, gemcitabine and nab-p…
This study is a Prospective Single Arm, dual cohort Open Label Feasibility trial to evaluate the initial safety and signal of efficacy of a novel extracorporeal…